SEC Form 4 · accession 0001144204-16-076144
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Gedeon Teper
Officer — CEO · Director · 10% Owner
Period of report
Jan 19, 2016
Accepted (ET)
Jan 19, 2016 · 6:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 19, 2016 | P | 44,200 | $0.5656 | A | 4,768,905 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported in this line item was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2015.